Leica Biosystems, a global leader in cancer diagnostics and workflow solutions, has acquired StatLab Medical Products for an undisclosed amount. This strategic acquisition significantly expands Leica Biosystems' offerings within the anatomic pathology market.
StatLab Medical Products, established in 1976, has built a strong reputation for supporting anatomic pathology laboratories with an extensive portfolio of self-manufactured consumables and labeling and tracking equipment. Operating from nine manufacturing sites across the United States, United Kingdom, Germany, Spain, and Italy, StatLab employs over 800 mission-driven colleagues. The company is known for its dependable and resilient supply chain, delivering high-quality products and solutions with a customer-centric approach focused on reliability, innovation, and quality.
The acquisition of StatLab is a strategic move for Leica Biosystems, aiming to strengthen its position in the anatomic pathology sector by integrating StatLab’s robust consumables and equipment portfolio. This combination will enable Leica Biosystems to offer a more comprehensive and integrated solution to its global customer base, enhancing its ability to provide end-to-end workflow solutions for laboratories. The synergy between Leica Biosystems’ advanced instrumentation and StatLab’s high-quality consumables is expected to streamline laboratory operations and improve overall efficiency.
By bringing together Leica Biosystems’ existing expertise and StatLab’s extensive manufacturing footprint and product range, the combined entity is poised to deliver enhanced value to anatomic pathology laboratories worldwide. This integration is expected to foster innovation in diagnostic solutions, ultimately contributing to improved diagnostic accuracy and patient care.